Enhancement of antibody immune response to a Toxoplasma gondii SAG1-encoded DNA vaccine by formulation with aluminum phosphate

Journal of Medical Sciences

Volumn 7, Issue 3, 2007, Pages 361-367

  Solhjoo, K ^a   Far, F Ghaffari ^a   Dalimi Asl, A ^a   Zharifi, Z ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

Author keywords

AIPO4; DNA vaccine; SAG1; Toxoplasma gondii

Indexed keywords

ALUMINUM PHOSPHATE; DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; PROTEIN P30;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG COST; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 34249895957     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2007.361.367     Document Type: Article

References (37)

1. Bhopale, G.M., 2003. Development of a vaccine for toxoplasmosis: Current status. Micro. Infect., 5: 457-462.
2. Biemans, R.,D. Gregoire, M. Haumont, A. Bosseloir and L. Garcia et al., 1998. The conformation of purified Toxoplasma gondii SAG1 antigen, secreted from engineered Pichia pastoris, is adequate for serorecognition and cell proliferation. J. Biotech., 66: 137-146.
3. Bonenfant, C., I. Dimier-Poisson, F. Velge-Roussel, D. Buzoni-Gantel and G.D. Giudice et al., 2001. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect. Immunol., 69: 1605-1612.
4. Brewer, J.M., M. Conacher, C.A. Hunter, M. Mohrs, F. Brombacher and J. Alexander, 1999. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J. Immunol., 163: 6448-6454.
5. Bülow, R. and J.C. Boothroyd, 1991. Protection of mice from fatal Toxoplasma gondii infection by immunization with p30 antigen in liposomes. J. Immunol., 147: 3496-3500.
6. Burg, J.L., D. Perelman, L.H. Kasper, P.L. Ware and J.C. Bothroyd, 1988. Molecular analysis of the gene encoding the major surface antigen of Toxoplasma gondii. J. Immunol., 141: 3584-3591.
7. Chen, X.G., Y. Gong, Hua-Li, Z-R. Lun and M-C. Fung, 2001. High-level expression and purification of immunogenic recombinant SAG1 (P30) of Toxoplasma gondii in Escherichia coli. Protein Expression and Purification, 23: 33-37.
8. Couper, K.N., H. Nielsen, E. Petersen, F. Roberts, C.W. Roberts and J. Alexander, 2003. DNA vaccination with the immunodominant tachyzoite surface antigen (SAG-1) protects against adult acquired Toxoplasma gondii infection but does not prevent maternofoetal transmission. Vaccine, 21: 2813-2820.
9. Crowther, J.R., 1995. ELISA, Theory and practice. Humana Press, New Jersey.
10. Debard, N., D. Buzoni-Gatel and D. Bout, 1996. Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect. Immunol., 64: 2158-2166.
11. Fachado, A., A. Rodriguez, S.O. Angel, D.C. Pinto and I. Vila et al., 2003. Protective effect of a naked DNA vaccine cocktail against lethal Toxoplasmosis in mice. Vaccine, 21: 1327-1335.
12. Fischer, L., J. Minke, N. Dufay, P. Baudu and J.C. Audonnet, 2003. Rabies DNA vaccine in the horse: Strategies to improve serological responses. Vaccine, 21: 4593-4596.
13. Guanjin, C., C. Haifeng, G. Hong and Z. Huanqin, 2002. Protective effect of DNA-mediated immunization with a combination of SAG1 and IL-2 gene adjuvant against of Toxoplasma gondii in mice. Chin. Med. J., 115: 1448-1452.
14. Gupta, R.K. and B.E. Rost, 2000. Aluminium Compounds as Vaccine Adjuvants. In: O'Hagan D.T., Ed. Methods in Molecular Medicine, Vaccine Adjuvants: Preparation Methods and Research Protocols, Humana Press Inc., 42: 65-89.
15. Haifeng, C., C. Guanjin, Z. Huanqin and G. Hong, 2003. Induction of immune responses in mice by vaccination with liposome-entrapped DNA complexes encoding Toxoplasma gondii SAG1 and ROP1 genes. Chin. Med. J., 116:1561-1566.
16. Kasper, L.H., K.M. Currie and M.S. Bradley, 1985. An unexpected response to vaccination with a purified major membrane tachyzoite antigen (P30) of Toxoplasma gondii. J. Immunol., 134: 3426-3431.Kimbita, E.N., X. Xuan, X. Huang, T. Miyazawa and S. Fukumoto et al., 2001. Serodiagnosis of Toxoplasma gondii infection in cat by enzyme-linked immunosorbent assay using recombinant SAG1. Vet. Parasitol., 102: 35-44.
17. Kwissa, M., E.B. Lindblad, R. Schirmeck and J. Reimann, 2003. Codelivery of a DNA vaccine and a protein vaccine with aluminium phosphate stimulates a potent and multivalent immune response. J. Mol. Med., 81: 502-510.
18. Laemmli, U.K., 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227: 680-685.
19. Letscher-Bru, V., O. Villard, B. Risse, M. Zauke, J-P. Klein and T.T. Kien, 1998. Protective effect of vaccination with a combination of recombinant surface antigen1 and interleukin-12 against Toxoplasmosis in mice. Infect. Immunol., 66: 4503-4506.
20. Letscher-Bru, V., A.W. Pfaff, A. Abou-Bacar, D. Filisetti and E. Antoni et al., 2003. Vaccination with Toxoplasma gondii SAG-1 Protein Is Protective against congenital Toxoplasmosis in BALB/c Mice but Not in CBA/J Mice. Infect. Immunol., 71: 6615-6619.
21. Lowry, D.H., N.J. Rosebraugh, A.L. Farr and R.J. Randall, 1951. Protein measurement with the folin phenol reagent. J. Biol. Chem., 93: 265-275.
22. Martin, V., M. Arcavi, G. Santillan, M.R. Armendoeira, E. De Souza Neves and G. Griemberg et al., 1998. Detection of human toxoplasma-specific immunoglobulins A, M and G with a recombinant T. gondii ROP2 protein. Clin. Diagn. Lab. Immunol., 5: 627-631.
23. Meek, B., R.J. Diepersloot, T.V. Gool, D. Speijer and R. Peek, 2003. IgM recognition of recombinant Toxoplasma gondii antigens by sera acutely or latently infected humans. Diag. Microbiol. Infect. Dis., 45: 45-52.
24. Mohamed, R.M., F. Aosai, M. Chen, H-S. Mun and K. Norose et al., 2003. Induction of protective immunity by DNA vaccination with Toxoplasma gondii HSP70, HSP30 and SAG1 genes. Vaccine, 21: 2852-2561.
25. Nielsen, H.V., S.L. LauemØller, L. Christiansen, S. Buus, A. Fomsggard and E. Petersen, 1999. Complete protection against Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Infect. Immunol., 67: 6358-6363.
26. Nigro, M., A. Gutierrez, A.M. Hoffer, M. Clemente and F. Kaufer et al., 2003. Evaluation of Toxoplasma gondii recombinant proteins for the diagnosis of recently acquired Toxoplasmosis by an immunoglobulin G analysis. Diagn. Microbiol. Infect. Dis., 47: 609-613.
27. Petersen, E., H.V. Nielsen, L. Christiansen and J. Spenter, 1998. Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii. Vaccine, 16: 1283-1289.
28. Rojas, P.A., V. Martin, M. Nigro, P.C. Echeverria and E.D. Guarnera et al., 2000. Expression of a cDNA encoding a Toxoplasma gondii protein belonging to the heat-shock 90 family and analysis of its antigenicity. FEMS Microbiol. Lett., 190: 209-213.
29. Rosado-Vallado, M., E. Dumonteil, R. Garcia-Miss Mdel and E. Dumonteil, 2005. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana. Vaccine, 23: 5372-5379.
30. Saito, S., F. Aosai, N. Rikihisa, H. Mun and K. Norose et al., 2001. Establishment of gene-vaccinated skin grafting against Toxoplasma gondii infction in mice. Vaccine, 19: 2172-2180.
31. Sambrook, J., E.F. Fritsch and T. Maniatis, 1989. Molecular Cloning: A Laboratory Manual, 2nd Edn., Cold Spring Harbor Laboratory Press.
32. Sasaki, S., F. Takeshita, K-Q. Xin, N. Ishii and K. Okuda, 2003. Adjuvant formulations and delivery systems for DNA vaccines. Methods, 31: 234-254.
33. Temperton, N.J., D.C. Quenelle, K.M. Lawson, J.N. Zuckerman, E.R. Kern and P.D. Griffiths et al., 2003. Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides. J. Med. Virol., 70: 86-90.
34. Ulmer, J.B., C.M. Dewitt, M. Chastain, A. Friedman, J.J. Donnelly and W.L. McClements et al., 1999. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine, 18: 18-28.
35. Velge-Roussel, F., P. Marcelo, A.C. Lepage, D. Buzoni-Gatel and D. Bout, 2000, Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into NALT and GALT compartments. Infect. Immunol., 68: 969-972.
36. Wang, S., X. Liu, K. Fisher, J.Z. Smith, F. Chen and T.W. Tobery et al., 2000. Enhanced type I immune response to hepatitis B DNA vaccine by formulation with calcium- or aluminium-phosphate. Vaccine, 18: 1227-1235.
37. Zinecker, C.F., B. Striepen, H. Geyer, R. Geyer and J-F. Dubremetz et al., 2001. Two glycoforms are present in the GPI-membrane anchor of the surface antigen 1(P30) of Toxoplasma gondii. Mole. Biochem. Parasitol., 116: 127-135.